Novel therapies and innovation for systemic sclerosis skin ulceration.
Capillaroscopy
Skin ulcer
Systemic sclerosis
Vasculopathy
Journal
Best practice & research. Clinical rheumatology
ISSN: 1532-1770
Titre abrégé: Best Pract Res Clin Rheumatol
Pays: Netherlands
ID NLM: 101121149
Informations de publication
Date de publication:
12 2022
12 2022
Historique:
medline:
22
5
2023
pubmed:
8
1
2023
entrez:
7
1
2023
Statut:
ppublish
Résumé
Skin ulceration is an important cause of morbidity in systemic sclerosis and can occur at anytime during disease progression. Incident disease cohorts are important for understanding whether skin ulceration represents active vasculopathy versus resultant damage. Biomarkers for skin ulcer pathogenesis, both serum and imaging, are under investigation to elucidate the functional consequences of the structural abnormalities. Novel therapeutics for the treatment of vasculopathy benefit from reliable biomarkers able to predict the disease evolution remains an important unmet need. Nonetheless, a diagnostic approach that captures early skin ulceration and treatments that restore vascular and immune homeostasis is critical for effective systemic sclerosis (SSc) vasculopathy management.
Identifiants
pubmed: 36609122
pii: S1521-6942(22)00072-9
doi: 10.1016/j.berh.2022.101813
pii:
doi:
Substances chimiques
Biomarkers
0
Types de publication
Journal Article
Review
Research Support, U.S. Gov't, Non-P.H.S.
Langues
eng
Sous-ensembles de citation
IM
Pagination
101813Subventions
Organisme : CSRD VA
ID : I01 CX002111
Pays : United States
Organisme : CSRD VA
ID : IK2 CX001785
Pays : United States
Informations de copyright
Copyright © 2022 Elsevier Ltd. All rights reserved.
Déclaration de conflit d'intérêts
Declaration of competing interest None declared.